全文获取类型
收费全文 | 24774篇 |
免费 | 2542篇 |
国内免费 | 494篇 |
专业分类
耳鼻咽喉 | 135篇 |
儿科学 | 485篇 |
妇产科学 | 721篇 |
基础医学 | 1332篇 |
口腔科学 | 1290篇 |
临床医学 | 3154篇 |
内科学 | 4067篇 |
皮肤病学 | 511篇 |
神经病学 | 1690篇 |
特种医学 | 311篇 |
外国民族医学 | 4篇 |
外科学 | 2387篇 |
综合类 | 2033篇 |
现状与发展 | 1篇 |
预防医学 | 2355篇 |
眼科学 | 252篇 |
药学 | 3335篇 |
9篇 | |
中国医学 | 1795篇 |
肿瘤学 | 1943篇 |
出版年
2024年 | 104篇 |
2023年 | 707篇 |
2022年 | 913篇 |
2021年 | 1487篇 |
2020年 | 1267篇 |
2019年 | 1325篇 |
2018年 | 1280篇 |
2017年 | 1177篇 |
2016年 | 1003篇 |
2015年 | 922篇 |
2014年 | 1927篇 |
2013年 | 2454篇 |
2012年 | 1376篇 |
2011年 | 1328篇 |
2010年 | 1082篇 |
2009年 | 1083篇 |
2008年 | 1118篇 |
2007年 | 1089篇 |
2006年 | 1004篇 |
2005年 | 895篇 |
2004年 | 715篇 |
2003年 | 569篇 |
2002年 | 500篇 |
2001年 | 365篇 |
2000年 | 291篇 |
1999年 | 269篇 |
1998年 | 218篇 |
1997年 | 167篇 |
1996年 | 149篇 |
1995年 | 116篇 |
1994年 | 124篇 |
1993年 | 74篇 |
1992年 | 80篇 |
1991年 | 68篇 |
1990年 | 73篇 |
1989年 | 65篇 |
1988年 | 53篇 |
1987年 | 45篇 |
1986年 | 40篇 |
1985年 | 53篇 |
1984年 | 45篇 |
1983年 | 33篇 |
1982年 | 19篇 |
1981年 | 28篇 |
1980年 | 25篇 |
1979年 | 21篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 10篇 |
1975年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
目的 评价控制性降压是否增加脊髓对牵拉损伤的易感性。材料与方法健康成年杂种犬6只,随机分为常压和控制性降压脊髓牵拉损伤组。观察常压及控制性降压水平下相同程度牵拉损伤后脊髓血流(SCBF)、体感诱发电位(SEP)、神经源性运动诱发电位(NMEP)改变的差异。结果 外周血有创动脉压(MABP)平均下降幅度为40.5%。经SSPS统计软件独立样本t检验,不同牵拉水平下,常压组及低压组的SCBF(%)、SEP波幅(Asep)(%)及NMEP波幅(%)无显著差异。结论 尼卡地平控制性降压不增加脊髓对牵拉损伤的易感性。 相似文献
62.
采用改性乙烯-醋酸乙烯共聚物(mEVA)作为控释材料制备释放左炔诺孕酮(LNG)4μg/d,预期使用寿命为5年的钥匙形宫内节育器(IUD)。本IUD在体外和在人及动物子宫内均为零级释药。释药速度与释药管管壁厚度或管外内径比的对数成反比,提示本释药体系的释药模武符合膜控制释药的特性。动物血药浓度测定结果表明,家兔子宫内植入IUD 2d后,血中LNG浓度趋于稳定。 相似文献
63.
64.
A simulation study of three sequential methods for the comparison of two treatment groups when the response criterion is censored 总被引:1,自引:0,他引:1
Three recent sequential methods, group sequential analysis (GSA), the sequential probability ratio test (SPRT) and the triangular test (TT) are well suited to randomized clinical trials with a censored response criterion, as they do not require matched pairs of patients. We undertook a simulation study to investigate their statistical properties and to compare these three methods with the fixed-sample design. Our results suggest that the three methods have the expected statistical properties for size and power; they allow an important reduction of the average number of events before stopping, except with GSA when there is no treatment difference; the triangular test (closed design) appears the optimal design, as the variance of the number of events is smaller than with the sequential probability ratio test (open design) and analysis after every twenty new events does not alter the statistical properties of these sequential methods and enhances their usefulness. 相似文献
65.
Lijun Di Jun Ren Ying Yan 《中德临床肿瘤学杂志》2007,6(4):393-395
Objective: To evaluate the effect and safety of clinical use of zoledronic acid in the treatment of malignant hypercalcemia. Methods: A multi-center, open phase II clinical trial was conducted in 15 cases with malignant hypercalcemia who received zoledronic acid intravenously for 15 min. The level of blood calcium and side effects were recorded regularly within 28 days after injection. Results: One case was dropped out due to bad compliance. The complete response rate (the corrected serum calcium was reduced to normal level) was 100.00% (14/14). The medium time of complete response rate was 5.07 days. The medium maintain time was 22.30 days. Slight, or moderate fever was observed. Conclusion: Zoledronic acid can effectively reduce the malignant hypercalcemia. The use of zoledronic acid appears to be safety and convenient. 相似文献
66.
复方18甲基炔诺酮/雌二醇透皮控释传递系统(LNG/E_2 TCDS)能同时恒速释放低剂量的LNG和E_2,在1周内维持一个平稳而有效的LNG血药浓度。药动学与药效学研究证明,该系统释放的LNG能达到血清LNG目标水平,产生有效的排卵抑制(6/6)。LNG/E_2 TCDS可望发展成为一种安全、有效、非侵入性的新型生育调节避孕制剂。 相似文献
67.
HA Carpay P Matthijsse M Steinbuch PGH Mulde 《Cephalalgia : an international journal of headache》1997,17(5):591-595
In an open, randomized cross-over study in 124 patients, we compared the efficacy, safety and patient preference of oral and subcutaneous sum triptan in the acute treatment of migraine. Patients were treated for 3 attacks or 3 months and then crossed over. Primary clinical efficacy was defined as a reduction in headache severity on a four-point self-rating scale from severe (3) or moderate (2) to mild (1) or none (0), or mild (1) to none (0). Efficacy was evaluated 2 h after the administration of subcutaneous and 4h after the administration of oral sumatriptan. Subcutaneous sumatriptan was significantly more effective than oral sumatriptan in relieving headache (over all three attacks 78% vs 61% improvement), improving clinical disability (55% vs 41 % improvement) and relieving nausea (69% vs 53%), vomiting (72% vs 32%) and phono- or photophobia (67% vs 49%). Median time to recurrence was shorter after subcutaneous (12.5 h) than after oral sumatriptan (18 h); the number of patients experiencing a recurrence was similar Patients reported more adverse events after subcutaneous sumatriptan (1.32 per attack) than after the oral form (0.85 per attack), but all adverse events were mild to moderate in intensity and of short duration. Patient opinion was more often positive after subcutaneous sumatriptan. These results may be useful in counselling patients to choose between the available marketed formulations of sumatriptan. 相似文献
68.
R. Lazzara A. A. Siddiqui P. Binon S. A. Feldman R. Weiner R. Phillips A. Gonshor 《Clinical oral implants research》1996,7(1):73-83
Osseointegrated dental implants have now become an accepted form of treatment for patients with a fully or partially missing dentition. The purpose of this study was to evaluate the performance of 3i threaded and cylindrical implants. During a 5-year period, a total of 1969 3i endosseous implants were placed at 6 centers in the United States and 2 elsewhere in the edentulous and partially edentulous jaws of 653 consecutive patients ranging in age from 18 to 82 years. Of the total number of implants placed, 1341 were commercially pure titanium threaded implants and 628 were titanium plasma-sprayed implants with a cylindrical configuration. A total of 28 patients with 110 implants were lost to follow-up. Implants in these patients were considered neither a success nor a failure. Success was predicated on the osseointegration of each and every implant followed in this analysis rather than the persistence of prosthetic function. Confirmed bone anchorage was considered essential for success. A total of 625 patients with 1871 implants remain in the study with a follow-up period ranging from 6 to 60 months. A total of 93 implants (5.0% of the total implants followed) were considered as failures. A mean implant survival rate was 95.0% for both the threaded and the cylindrical implant was calculated. The success rate of threaded implants was 97.0% in the mandible and 93.8% in the maxilla. The success rate for the 3.3mm cylindrical implants was 96.0% in the mandible and 95.5% in the maxilla, and the success rate of 4.0mm diameter cylindrical implants was 95% in the mandible and 92.0% in the maxilla. Causes of failure consisted of loss of osseointegration 2.3%crestal bone loss requiring periodontal therapy after the first year of function 1.7% and mechanical problems associated with the prosthesis 0.9%. This retrospective analysis of the 3i endosseous implant system is comparable to previous reports on other implant systems in terms of implant survival and prosthesis stability. It is demonstrated that 3i implants are predictable and can provide lasting osseointegration leading to improvement of oral function if the recommended surgical and restorative protocol is followed. 相似文献
69.
Sintov Amnon Scott William A. Gallagher Kim P. Levy Robert J. 《Pharmaceutical research》1990,7(1):28-33
Epicardial antiarrhythmic drug administration was studied as a therapeutic approach for experimental ventricular tachycardia (VT) in an open-chest dog model. Lidocaine-polyurethane matrices (28%, w/w) were formulated as a model system. Matrices were placed on the left ventricular epicardium in each of 23 anesthetized open-chest dogs with ouabain-induced VT, to evaluate effectiveness in restoring sinus rhythm. Conversion occurred in all animals treated with matrices containing 300 mg or more of lidocaine after 1.5 to 7.0 min. The matrix lidocaine content correlated linearly with the time required for conversion to sinus rhythm (r = 0.75, P = 0.0002); irrespective of matrix size the myocardial/plasma lidocaine ratio was 20.1 ± 4.2 (mean ± SD) at the time of conversion. In a separate series of five dogs without ventricular tachycardia, systolic wall thickening measured with sonomicrometers after 5 min of controlled-release lidocaine administration (500- to 1000-mg matrix lidocaine content, 7.48 ± 3.49-mg/kg dose) was only minimally diminished (–14.1%) and this effect was observed only at the site of matrix placement on the anterior-apical epicardium. In contrast, intracoronary injection of 0.3 or 1.0 mg/kg of lidocaine-HCl resulted in complete elimination of wall thickening or replacement by systolic thinning. Thus epicardial administration of lidocaine from polyurethane matrices was an effective means of treating ouabain-induced ventricular tachycardia. Regional myocardial function in the vicinity of the matrices was modified to a very limited degree, supporting the view that the matrices can be used safely, without serious risk to ventricular contractile performance. 相似文献
70.
C. J. Bowden W. D. Figg N. A. Dawson O. Sartor R. J. Bitton M. S. Weinberger Donna Headlee Eddie Reed C. E. Myers M. R. Cooper 《Cancer chemotherapy and pharmacology》1996,39(1-2):1-8
Introduction: Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis,
but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent. Objective: This clinical trial of suramin was undertaken as a phase I/II study in patients with hormone-refractory prostate cancer,
with the hypothesis that the intensity of therapy with suramin could be increased significantly if measures were undertaken
to maintain the plasma concentrations of the drug under 300 μg/ml. Methods: We report the clinical results of this trial, wherein patients were treated at three different targeted plasma suramin concentrations
(275, 215 and 175 μg/ml) for varying periods of time (2, 4 or 8 weeks), with delivery of the drug by continuous intravenous
infusion. Results: The major toxicity observed in this trial was neurologic, consisting of a motor and sensory peripheral neuropathy that resulted
in both paresis and paralysis of the limbs. Nearly all of this severe (CTEP grade III, IV) neurologic toxicity was observed
in the patients treated at a plasma suramin concentration of 275 μg/ml for 4 or more weeks. A single patient treated at 215 μg/ml
for 8 weeks developed moderate (CTEP grade III) proximal lower extremity weakness, and no patient treated at 175 μg/ml developed
this toxicity. The second most common toxicity observed was infection of the central venous catheter. The overall response
rate for all of the evaluable patients was 17% (13 of 75 patients). In addition, prostate-specific antigen (PSA)-defined responses
were observed in six patients receiving therapy at 175 μg/ml, but these responses were confounded by cessation of therapy
with flutamide during suramin treatment. Conclusions: In summary, although plasma suramin concentrations were maintained below 300 μg/ml, neurologic toxicity nonetheless occurred
with high frequency in patients treated at 275 μg/ml for 4 or more weeks. Therapy at 215 and 175 μg/ml was in general well
tolerated, but central venous catheter-related infection, as well as the inconvenience and expense of continuous infusional
therapy, make this method of drug delivery impractical. Only moderate antitumor activity was observed during this trial, but
it is possible that both continuation of flutamide and flutamide withdrawal during suramin therapy confounded the assessment
of suramin’s activity in hormone-refractory prostate cancer.
Received: 9 June 1995/Accepted: 18 March 1996 相似文献